Citations

Clear

117 citation(s) found for "Carson, C C".

BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5–18 Years—United States, July 2021 – April 2022
Zambrano, Laura D. , Newhams, Margaret M. , Olson, Samantha M. , Halasa, Natasha , Price, Ashley M. , Orzel, Amber, Boom, Julie A. , Bline, Katherine , Kamidani, Satoshi , Tarquinio, Keiko M. , Schuster, Jennifer E. , Cullimore, Melissa L. , Heidemann, Sabrina M. , Nofziger, Ryan A. , Cameron, Melissa A. , Walker, Tracie C. , Michelson, Kelly N, Coates, Bria M. , Flori, Heidi R. , Mack, Elizabeth H. , Smallcomb, Laura , Gertz, Shira J. , Bhumbra, Samina S. , Bradford, Tamara T. , Levy, Emily R. , Kong, Michele , Irby, Katherine, Zinter, Matt S. , Bowens, Cindy, Crandall, Hillary , Hume, Janet R. , Patel, Manish M, Campbell, Angela P. , Randolph, Adrienne G. , Investigators, for the Overcoming COVID-19, Murdock, Meghan, Gaspers, Mary Glas , Kelley, Connor P. , Irby, Katherine, Sanders, Ronald C., Yates, Masson, Smith, Chelsea , Crane, Katheryn, Lionetti, Geraldina, Murcia-Montoya, Juliana, Villarreal-Chico, Denise, Skura, Adam L., Hakimi, Daniel , Peralta, Harvey, Sea, Yea Ji, Mrotek, Kennis-Grace, Lockwood, Justin M. , Port, Emily, Carson, Imogene A., Chatani, Brandon , Kamidani, Satoshi, Hussaini, Laila, Baida, Nadine, Michelson, Kelly N, Rhodes, Simone T., Khan, Hassan A, Rowan, Courtney M. , Stumpf, Mary, Johnston, Marla , Newhams, Margaret M, Kücükak, Suden, Orzel, Amber O, Chen, Sabrina R., Boutselis, Benjamin J., McCadden, Timothy P. , Stewart, Kasey R, Weller, Edie, Berbert, Laura , He, Jie , Bruno, Ellen R., Goertzen, Lexie A., Drapeau, Noelle M., Martin, Lora , Malloch, Lacy , Harrison, Virginia A., Sanders, Cameron , Patterson, Kayla , Chikere, Chidinma A, Kietzman, Abigail , Sullivan, Melissa, Rinehart, Valerie H., Hoody, Lauren A., Bennett, Paris C., Twinem, Nicole A., Tomcany, Merry, Staat, Mary Allen , Rohlfs, Chelsea C., Wolfe, Amber, Chiotos, Kathleen, Douglas, Rebecca L. , Phengchomphet, Kathlyn, Bickford, Megan M., Wakefield, Lauren E., Hayek, Haya , Romero, Yesenia, Boom, Julie A, Oates, Jennifer N., Maamari, Mia , Bowens, Cindy, Olson, Mady, Zambrano, Laura D, Patel, Manish M, Kamidani, Satoshi , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Hume, Janet R , Zambrano, Laura D , Staat, Mary A , Gertz, Shira J , Bline, Katherine E , Young, Cameron C. , Sahni, Leila C , Maddux, Aline B. , Chiotos, Kathleen , Hobbs, Charlotte V. , Pannaraj, Pia S. , Schwartz, Stephanie P. , Michelson, Kelly N, Irby, Katherine, Cvijanovich, Natalie Z , Bowens, Cindy, Patel, Manish M, Investigators, for the Overcoming COVID-19, Typpo, Katri , Irby, Katherine, Kamidani, Satoshi, Michelson, Kelly N, Newhams, Margaret M, Orzel, Amber O, Moran, Patrick, Behl, Supriya , Chiotos, Kathleen, Boom, Julie A, Bowens, Cindy, Olson, M, Zambrano, Laura D, Patel, Manish M

Mayo Clinic

Clinical Infectious Diseases | August 4, 2022 | Volume: 76 | Issue: 3 | Pages: e90-e100

10.1093/cid/ciac637 | PMID 35924406 Get It

Abstract Background Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood. Methods In a multicenter, case-control, public health investigation of children ages 5–18 years hospitalized from 1 July 2021 to 7 April 2022, we compared the odds of being fully vaccinated (2 doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression. Results We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (adjusted OR [aOR]: .16; 95% CI: .10–.26), including among children ages 5–11 years (aOR: .22; 95% CI: .10–.52), ages 12–18 years (aOR: .10; 95% CI: .05–.19), and during the Delta (aOR: .06; 95% CI: .02–.15) and Omicron (aOR: .22; 95% CI: .11–.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR: .08; 95% CI: .03–.22) in 12–18-year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible case-patients were unvaccinated. Conclusions Vaccination with 2 doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5–18 years. Most vaccine-eligible hospitalized patients with MIS-C were unvaccinated.
ASHP Statement on Telehealth Pharmacy Practice
Begnoche, Brendan R, Butler, Charlotte, Carson, Paige H, Darr, Andrea, Jenkins, Matthew T. , McDaniel, Robert B, Mourad, Hesham , Shipman, Colleen J., Stratton, Timothy P., Tran, Kelvin , Butler, C David, Jenkins, Matthew T, Le, Trinh , Tran, Kelvin, Wong, Kong (Kit)

Mayo Clinic

American Journal of Health-System Pharmacy | July 22, 2022 | Volume: 79 | Issue: 19 | Pages: 1728-1735

10.1093/ajhp/zxac188 | PMID 35866463 Get It

Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
Voorhees, Peter M. , Goldschmidt, Hartmut , Shi, Yingqi , Rousseau, Els, Dennis, Robyn Monet, Carson, Robin, Dimopoulos, Meletios Α. , Baker, Ross , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS8075-TPS8075

10.1200/jco.2022.40.16_suppl.tps8075 Get It

TPS8075 Background: Standard of care for SMM includes active monitoring until progression to multiple myeloma (MM); however, recent evidence suggests pts with high-risk features may benefit from early treatment. DARA is a human IgGκ monoclonal antibody targeting CD38 that is approved as monotherapy for relapsed/refractory MM (RRMM) or in combination with standard of care for RRMM or newly diagnosed MM. Results from the phase 3 COLUMBA study showed that DARA SC demonstrated similar efficacy to intravenous (IV) DARA but with a lower rate of infusion-related reactions and shorter administration time. Based on the promising single-agent activity observed with IV DARA in intermediate- or high-risk SMM pts during the phase 2 CENTAURUS study, we hypothesized that DARA SC may delay progression to MM versus active monitoring in pts with high-risk SMM. Methods: AQUILA is an ongoing, randomized, open-label, multicenter phase 3 study of DARA SC versus active monitoring in pts with high-risk SMM. DARA SC (DARA 1,800 mg + recombinant human hyaluronidase PH20 [rHuPH20; 2,000 U/mL; Halozyme]) is administered by manual injection over approximately 5 minutes at alternating locations on the abdomen weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and every 4 weeks thereafter until 39 cycles (28 days/cycle), up to 36 months, or until disease progression. Eligibility criteria include confirmed diagnosis of SMM for ≤5 years, factors indicating high risk of progression to MM (clonal bone marrow plasma cells [BMPCs] ≥10% and ≥1 of the following: serum M protein ≥30 g/L, IgA SMM, immunoparesis with reduction of 2 uninvolved Ig isotypes, serum involved:uninvolved free light chain ratio ≥8 to < 100, or clonal BMPCs > 50% to < 60% with measurable disease), and ECOG performance status ≤1. The primary endpoint is progression-free survival (PFS), assessed by an independent review committee, with disease progression defined according to International Myeloma Working Group diagnostic criteria for MM. Secondary endpoints include time to biochemical or diagnostic (SLiM-CRAB) progression, overall response rate, complete response rate, duration of response, time to response, time to first-line treatment for MM, PFS on first-line treatment for MM (PFS2), overall survival, and incidence of MM with adverse prognostic features. The study completed enrollment on May 6, 2019; 390 pts have been randomly assigned to DARA SC or active monitoring. The primary efficacy analysis will be performed after approximately 165 PFS events have been observed. Clinical trial information: NCT03301220.
The role of cytokines and their antagonists in the treatment of COVID‐19 patients
Afshar, Zeinab Mohseni , Barary, Mohammad , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Tavakoli Pirzaman, Ali , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Ebrahimpour, Soheil , Barary, Mohammad

Mayo Clinic

Reviews in Medical Virology | May 27, 2022 | Volume: 33 | Issue: 1 | Pages: No page available

10.1002/rmv.2372 | PMID 35621229 Get It

AbstractThe coronavirus disease 2019 (COVID‐19) has various presentations, of which immune dysregulation or the so‐called cytokine storm syndrome (COVID‐CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID‐19 infections, caused by the excessive release of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, IL‐8, tumour necrosis factor, granulocyte‐macrophage colony‐stimulating factor, and interferon‐gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin‐6 receptor blocker approved to treat severe COVID‐19 infections.
Diabetes Rescue, Engagement and Management (D-REM): rationale and design of a pragmatic clinical trial of a community paramedicine programme to improve diabetes care
Juntunen, Michael B. , Liedl, Chad P., Carlson, Peter N., Stickler, Zachary R., Schultz, Jill A Ryan, MEILANDER, ANGELA K., Behnken, Emma , Rogerson, M Carson, Myers, Lucas A. , Ryan Schultz, Jill A, Lampman, Michelle A. , McCoy, Rozalina Grubina , Schultz, Jill Ryan, Fischer, Karen M. , McCoy, Rozalina G.

Mayo Clinic

BMJ Open | May 17, 2022 | Volume: 12 | Issue: 4 | Pages: e057224

10.1136/bmjopen-2021-057224 | PMID 35450906 Get It

Introduction Diabetes is one of the most common serious chronic health conditions in the USA. People living with diabetes face multiple barriers to optimal diabetes care, including gaps in access to medical care and self-management education, diabetes distress, and high burden of treatment. Community paramedics (CPs) are uniquely positioned to support multidisciplinary care for patients with diabetes by delivering focused diabetes self-management education and support and bridging the gaps between patients and the clinical and community resources they need to live well with their disease. Methods and analysis We will conduct a pragmatic single-arm prospective trial of a CP-led Diabetes Rescue, Engagement and Management (D-REM) programme that seeks to reduce diabetes distress. We will enrol 70 adults (≥18 years) with diabetes who have haemoglobin A1c (HbA1c)≥9.0%, experienced an emergency department (ED) visit or hospitalisation for any cause within the prior 6 months, and reside in areas with available CP support in Southeast Minnesota (Olmsted, Freeborn and Mower counties) and Northwest Wisconsin (Barron, Rusk and Dunn counties). Participants will be identified using Mayo Clinic electronic health records, contacted for consent and enrolled into the D-REM programme. Visit frequency will be individualised for each patient, but will be an average of four CP visits over the course of approximately 1 month. Outcomes will be change in diabetes distress (primary outcome), confidence in diabetes self-management, health-related quality of life, self-reported hypoglycaemia and hyperglycaemia, HbA1c, ED visits and hospitalisations. Outcomes will be assessed on enrolment, programme completion and 3 months after programme completion. Ethics and dissemination The study was approved by Mayo Clinic Institutional Review Board. Findings will be disseminated through peer-reviewed publications and presentations. If demonstrated to be successful, this model of care can be implemented across diverse settings and populations to support patients living with diabetes. Trial registration number NCT04385758 .
Remdesivir: A critical review
Afshar, Zeinab Mohseni , Hosseinzadeh, Dariush , Allahgholipour, Amirreza , Carson‐Chahhoud, Kristin , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil , Barary, Mohammad , Carson-Chahhoud, Kristin , Babazadeh, Arefeh , Sio, Terence T. , Sullman, Mark J. M.

Mayo Clinic

No container title available | May 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165156484.47824744/v1 Get It

Remdesivir has appeared to be the most effective medication against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to the coronavirus disease 2019 (COVID-19) patients around the world. Remdesivir is an RNA polymerase inhibitor with a broad spectrum of antiviral activities against RNA viruses in in-vitro and in-vivo models of SARS-CoV, the Middle East respiratory syndrome (MERS), and SARS-CoV-2. Remdesivir is the first Food and Drug Administration (FDA) approved anti-SARS-CoV-2 treatment for adult and pediatric patients and has been used intravenously for patients requiring hospitalization for COVID-19. However, questions have been raised about the value of remdesivir in treating COVID-19, and governing bodies worldwide have been hesitant to approve this medication. Nevertheless, in the context of the public health emergency and the urgent need for effective treatments for patients with COVID-19, remdesivir has been approved by several authorities worldwide. Here, we discuss characteristics and applications of remdesivir, and various challenging studies with different outcomes about its efficacy are also reviewed.
P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
Sonneveld, Pieter , Chanan‐Khan, A.A., Spicka, I, Munder, Markus , Mateos, MV, Mark, TM, Levin, M-D, Ahmadi, T., Qin, Xiang , Mayo, Wendy Garvin, Gai, X, Carey, Jodi, Carson, Robin, Spencer, Andrew , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Spicka, I, Hungria, Vânia

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 12-12

10.1097/01.hs9.0000829588.31575.a9 Get It